Global /Canada /Healthcare /Biotechnology /MDCX

Medicus Pharma Ltd.

MDCX

• NASDAQ: MDCX • Delayed

0.2936USD -2.1%

As of 5 June 2026, Medicus Pharma Ltd. has a market cap of $11.56M USD, ranking #40485 globally and #1581 in Canada. It ranks #3600 in the Healthcare sector, and #707 in the Biotechnology industry.

Global Rank

40485

Country Rank

1581

Sector Rank

3600

Industry Rank

707

Key Stats

Market Cap

$11.56MUSD

Enterprise Value

$8.07MUSD

Net Income (TTM)

-$47.28MUSD

PB Ratio

302.9

Company Profile

Country (HQ)

Canada

Sector

Healthcare

Industry

Biotechnology

CEO

Raza Bokhari open_in_new

Employees

Founded

2008

Website

medicuspharma.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2.1%	-12%	-36%	-76%	-88%	-81%	-93%	-88%	-88%

News

MDCX Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	MDCX Medicus Pharma Ltd ISIN: CA58471K2020 Shares Out.: Shares Outstanding: 11.817M¹ Shares Float: 9.611M² TV: TradingView: NASDAQ: MDCX SA: Stock Analysis: NASDAQ: MDCX YF: Yahoo Finance: MDCX GF: Google Finance: NASDAQ: MDCX NQ: NASDAQ: MDCX BA: Barron's: MDCX MS: Morningstar: XNAS: MDCX	0.2936 USD	TV: TradingView: NASDAQ: MDCX SA: Stock Analysis: NASDAQ: MDCX YF: Yahoo Finance: MDCX GF: Google Finance: NASDAQ: MDCX NQ: NASDAQ: MDCX BA: Barron's: MDCX MS: Morningstar: XNAS: MDCX

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Medicus Pharma Ltd.

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in West Conshohocken, Pennsylvania.

Similar Companies

Industry: Biotechnology (Canada)

Name	Market Cap (USD) diff.	PE	Country
Aurinia Pharmaceuticals Inc. NASDAQ: AUPH	$1.99B 17K%	7.4	Canada
AbCellera Biologics Inc. NASDAQ: ABCL	$1.16B 10K%	-	Canada
Eupraxia Pharmaceuticals Inc. TSX: EPRX	$432.32M 600.89M CAD 4K%	-	Canada
NervGen Pharma Corp. TSXV: NGEN	$295.12M 410.19M CAD 2K%	-	Canada
Cybin Inc. NEO: CYBN	$254.07M 353.13M CAD 2K%	-	Canada
Cardiol Therapeutics Inc. TSX: CRDL	$149.71M 208.08M CAD 1K%	-	Canada

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 2M%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 1M%	19.0	United States
argenx SE EBR: ARGX	$48.01B 41.39B EUR 415K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.48B 68.19T KRW 385K%	35.5	South Korea
CSL Ltd. ASX: CSL	$43.01B 60.27B AUD 372K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.55B 33.71B CHF 368K%	37.2	Switzerland

chevron_leftBack